The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges

  1. González-Larriba, J.L.
  2. Maroto, P.
  3. Durán, I.
  4. Lambea, J.
  5. Flores, L.
  6. Castellano, D.
  7. Anido, U.
  8. Basterrechea, L.
  9. Casanovas, O.
  10. Chirivella, I.
  11. Climent, M.Á.
  12. Dur, I.
  13. Gallardo, E.
  14. Garc, R.
  15. Guix, M.
  16. Laínez, N.
  17. Marino, A.M.
  18. Montesa, Á.
  19. Pinto, A.
  20. Puente, J.
  21. Romero, G.R.
  22. Suárez, C.
  23. Virizuela, J.A.
Journal:
Expert Review of Anticancer Therapy

ISSN: 1744-8328 1473-7140

Year of publication: 2017

Volume: 17

Issue: 3

Pages: 217-226

Type: Review

DOI: 10.1080/14737140.2017.1273774 GOOGLE SCHOLAR

Sustainable development goals